chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Ultrasound Doppler abnormal
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 02/21, Pfizer, dose #1 03/10, Pfizer, dose #2 08/31 pt cc: cough, diarrhea, dyspnea exposure: unknown 08/31 COVID swab, result: detected 08/31 SARS-COV-2 LINEAGE AY.25 08/31 SARS-COV-2 CLADE 21 J DELTA 09/01 pt admit to Medicine cc: cough and leg edema dx: covid 19 pneumonia LOS: 10 days 09/01 CXR impression: Bilateral airspace disease. Correlate clinically for pneumonia including viral/atypical etiology and follow-up to resolution 09/01 US extremity impression: 1. Right lower extremity: Findings suggestive of a subtle nonocclusive thrombus in the deep femoral vein. 2. Left lower extremity: Mild mural irregularity and echogenicity focally in the mid/distal femoral vein perhaps from a chronic nonocclusive thrombus 09/01 CTA PE impression: 1. No evidence of pulmonary embolism or dissection. 2. Patchy peripheral groundglass and consolidative opacities which can be seen with a history of Covid. 3. Stenosis of the left lung bronchi which is likely due to position however recommend contrast enhanced CT after resolution of acute infection. 4. Severe degenerative changes of the spine status post cervical and lumbar. Bones are diffusely osteopenic. Multiple compression fractures. The critical result of follow-up CT for bronchial stenosis was communicated to Dr. on 9/1/2021 at 21:07 with read-back verification. 09/01 PROCALCITONIN results: <0.05 09/01 DDIMER result: 0.74 09/02 CXR impression: Similar-appearing retrocardiac and right infrahilar opacities suspicious for pneumonia. 09/02 ESR result: 10 09/02 Fibrinogen result: 261 09/02 DDIMER result: 0.79 09/03 ESR result: 9 09/03 Fibrinogen result: 240 09/03 DDIMER result: 0.52 09/04 ESR result: 11 09/04 Fibrinogen result: 200 09/04 DDIMER result: 0.78 09/05 ESR result: 5 09/05 Fibrinogen result: 207 09/05 DDIMER result: 0.90 09/06 ESR result: 9 09/06 Fibrinogen result: 228 09/06 DDIMER result: 1.03 09/07 ESR result: 3 09/07 Fibrinogen result: 245 09/07 DDIMER result: 0.69 09/08 ESR result: 9 09/08 Fibrinogen result: 264 09/08 DDIMER result: 0.97 09/10 clinically resolved
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative:  83yo patient who does not receive medical care from the agency receive covid vaccines from the agency on 3/19/2021 & 4/16/2021. Agency was informed pt died on 9/29/2021. No information available regarding pt's medical history or cause of death. Likely death is unrelated to covid vaccines given pt's advance age and length of time between death and dates covid vaccines were given.
Age: 81.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Acute respiratory failure, Angiogram pulmonary abnormal, Aortic arteriosclerosis, Arterial catheterisation, Arteriosclerosis coronary artery
Clinical narrative: Narrative: Admission date: Oct 10,2021 Discharge Date: Oct 22,2021 Condition of patient at discharge: DECEASED Primary Diagnosis during Admission/Treatment: Acute Hypoxic Respiratory Failure (AHRF) secondary to COVID Pneumonia 80 year old male with a history of CAD s/p PCI to LAD, HFrecEF (51% 12/2020, prev 35% 5/2020) s/p BiV-ICD 9/2020, HTN, and hypothyroidism presented to the Emergency Department (ED) with shortness of breath, cough, and weakness onset 2 weeks prior to the ED visit. Pt stated that he had progressively felt more fatigued and SOB with minimal exertion over the past two weeks and was encouraged to come to the ED by his nephew. He had greenish-yellow sputum production. He also admitted to 2 episodes of non-bloody, nonbilious emesis this morning. He denied any recent CP, lower extremity edema, or subjective fevers at home. In the ED, pt was afebrile, initially satting in the 80's on room air, BP 129/89, tachypneic RR 28. He tested positive for COVID-19 despite 2 doses of Moderna Covid vaccine on 1/11/2021 and 2/8/2021, and had notable labs of Cr 1.45, WBC 18.2, CRP 31.74, ESR 86, procal 1.75, ddimer 2.13. CXR showed mild atelectsis in left lower lobe otherwise clear. CTA PULMONARY ANGIOGRAPHY showed diffuse bilateral peripheral predominant areas of groundglass opacity and crazy paving in the lungs. VBG was 7.44/33.5/13. He was started on CAP coverage rocephin/azithro, given solumedrol 125mg and admitted to the ICU. The patient was started on 10-day course of steroids, remdesivir, and was given antibiotics to cover for possible bacterial co-infection during hospitalization. He started on High Flow Nasal Cannula (HFNC) on maximum settings with oxygen saturations that continued to drop below 88%. Patient was advised to self-prone, but stated that he was not able to do secondary to posture-related back pain. Remdesivir was discontinued after 2 days due to acute rise in liver function tests. Over the next few days, the patient began requiring a non-rebreather on 100% in addition to 60L 100% FiO2 HFNC to maintain oxygen saturation. On the morning of 10/22/21, patient began to decompensate with 75% oxygen saturation on 60L 100% HFNC with 100% non rebreather. After reviewing code status with the patient, he requested to be intubated, understanding the risks, benefits, and alternatives. Shortly following successful intubation with 100% FiO2 and PEEP of 14 and arterial line placement, patient continued to decompensate with HR near 130 and hypotension. Despite initiation of vasopressor and optimizing ventilator settings, patient declined and passed away on 10/22/2021 at 10:48am.
Age: 81.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Asthenia, Atelectasis, Back pain, Blood creatinine increased, Blood pH normal
Clinical narrative: Narrative: Admission date: Oct 10,2021 Discharge Date: Oct 22,2021 Condition of patient at discharge: DECEASED Primary Diagnosis during Admission/Treatment: Acute Hypoxic Respiratory Failure (AHRF) secondary to COVID Pneumonia 80 year old male with a history of CAD s/p PCI to LAD, HFrecEF (51% 12/2020, prev 35% 5/2020) s/p BiV-ICD 9/2020, HTN, and hypothyroidism presented to the Emergency Department (ED) with shortness of breath, cough, and weakness onset 2 weeks prior to the ED visit. Pt stated that he had progressively felt more fatigued and SOB with minimal exertion over the past two weeks and was encouraged to come to the ED by his nephew. He had greenish-yellow sputum production. He also admitted to 2 episodes of non-bloody, nonbilious emesis this morning. He denied any recent CP, lower extremity edema, or subjective fevers at home. In the ED, pt was afebrile, initially satting in the 80's on room air, BP 129/89, tachypneic RR 28. He tested positive for COVID-19 despite 2 doses of Moderna Covid vaccine on 1/11/2021 and 2/8/2021, and had notable labs of Cr 1.45, WBC 18.2, CRP 31.74, ESR 86, procal 1.75, ddimer 2.13. CXR showed mild atelectsis in left lower lobe otherwise clear. CTA PULMONARY ANGIOGRAPHY showed diffuse bilateral peripheral predominant areas of groundglass opacity and crazy paving in the lungs. VBG was 7.44/33.5/13. He was started on CAP coverage rocephin/azithro, given solumedrol 125mg and admitted to the ICU. The patient was started on 10-day course of steroids, remdesivir, and was given antibiotics to cover for possible bacterial co-infection during hospitalization. He started on High Flow Nasal Cannula (HFNC) on maximum settings with oxygen saturations that continued to drop below 88%. Patient was advised to self-prone, but stated that he was not able to do secondary to posture-related back pain. Remdesivir was discontinued after 2 days due to acute rise in liver function tests. Over the next few days, the patient began requiring a non-rebreather on 100% in addition to 60L 100% FiO2 HFNC to maintain oxygen saturation. On the morning of 10/22/21, patient began to decompensate with 75% oxygen saturation on 60L 100% HFNC with 100% non rebreather. After reviewing code status with the patient, he requested to be intubated, understanding the risks, benefits, and alternatives. Shortly following successful intubation with 100% FiO2 and PEEP of 14 and arterial line placement, patient continued to decompensate with HR near 130 and hypotension. Despite initiation of vasopressor and optimizing ventilator settings, patient declined and passed away on 10/22/2021 at 10:48am.
Age: 81.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: C-reactive protein increased, COVID-19, COVID-19 pneumonia, Cardiac failure, Chest X-ray abnormal
Clinical narrative: Narrative: Admission date: Oct 10,2021 Discharge Date: Oct 22,2021 Condition of patient at discharge: DECEASED Primary Diagnosis during Admission/Treatment: Acute Hypoxic Respiratory Failure (AHRF) secondary to COVID Pneumonia 80 year old male with a history of CAD s/p PCI to LAD, HFrecEF (51% 12/2020, prev 35% 5/2020) s/p BiV-ICD 9/2020, HTN, and hypothyroidism presented to the Emergency Department (ED) with shortness of breath, cough, and weakness onset 2 weeks prior to the ED visit. Pt stated that he had progressively felt more fatigued and SOB with minimal exertion over the past two weeks and was encouraged to come to the ED by his nephew. He had greenish-yellow sputum production. He also admitted to 2 episodes of non-bloody, nonbilious emesis this morning. He denied any recent CP, lower extremity edema, or subjective fevers at home. In the ED, pt was afebrile, initially satting in the 80's on room air, BP 129/89, tachypneic RR 28. He tested positive for COVID-19 despite 2 doses of Moderna Covid vaccine on 1/11/2021 and 2/8/2021, and had notable labs of Cr 1.45, WBC 18.2, CRP 31.74, ESR 86, procal 1.75, ddimer 2.13. CXR showed mild atelectsis in left lower lobe otherwise clear. CTA PULMONARY ANGIOGRAPHY showed diffuse bilateral peripheral predominant areas of groundglass opacity and crazy paving in the lungs. VBG was 7.44/33.5/13. He was started on CAP coverage rocephin/azithro, given solumedrol 125mg and admitted to the ICU. The patient was started on 10-day course of steroids, remdesivir, and was given antibiotics to cover for possible bacterial co-infection during hospitalization. He started on High Flow Nasal Cannula (HFNC) on maximum settings with oxygen saturations that continued to drop below 88%. Patient was advised to self-prone, but stated that he was not able to do secondary to posture-related back pain. Remdesivir was discontinued after 2 days due to acute rise in liver function tests. Over the next few days, the patient began requiring a non-rebreather on 100% in addition to 60L 100% FiO2 HFNC to maintain oxygen saturation. On the morning of 10/22/21, patient began to decompensate with 75% oxygen saturation on 60L 100% HFNC with 100% non rebreather. After reviewing code status with the patient, he requested to be intubated, understanding the risks, benefits, and alternatives. Shortly following successful intubation with 100% FiO2 and PEEP of 14 and arterial line placement, patient continued to decompensate with HR near 130 and hypotension. Despite initiation of vasopressor and optimizing ventilator settings, patient declined and passed away on 10/22/2021 at 10:48am.
Age: 81.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Cough, Death, Dyspnoea, Dyspnoea exertional, Endotracheal intubation
Clinical narrative: Narrative: Admission date: Oct 10,2021 Discharge Date: Oct 22,2021 Condition of patient at discharge: DECEASED Primary Diagnosis during Admission/Treatment: Acute Hypoxic Respiratory Failure (AHRF) secondary to COVID Pneumonia 80 year old male with a history of CAD s/p PCI to LAD, HFrecEF (51% 12/2020, prev 35% 5/2020) s/p BiV-ICD 9/2020, HTN, and hypothyroidism presented to the Emergency Department (ED) with shortness of breath, cough, and weakness onset 2 weeks prior to the ED visit. Pt stated that he had progressively felt more fatigued and SOB with minimal exertion over the past two weeks and was encouraged to come to the ED by his nephew. He had greenish-yellow sputum production. He also admitted to 2 episodes of non-bloody, nonbilious emesis this morning. He denied any recent CP, lower extremity edema, or subjective fevers at home. In the ED, pt was afebrile, initially satting in the 80's on room air, BP 129/89, tachypneic RR 28. He tested positive for COVID-19 despite 2 doses of Moderna Covid vaccine on 1/11/2021 and 2/8/2021, and had notable labs of Cr 1.45, WBC 18.2, CRP 31.74, ESR 86, procal 1.75, ddimer 2.13. CXR showed mild atelectsis in left lower lobe otherwise clear. CTA PULMONARY ANGIOGRAPHY showed diffuse bilateral peripheral predominant areas of groundglass opacity and crazy paving in the lungs. VBG was 7.44/33.5/13. He was started on CAP coverage rocephin/azithro, given solumedrol 125mg and admitted to the ICU. The patient was started on 10-day course of steroids, remdesivir, and was given antibiotics to cover for possible bacterial co-infection during hospitalization. He started on High Flow Nasal Cannula (HFNC) on maximum settings with oxygen saturations that continued to drop below 88%. Patient was advised to self-prone, but stated that he was not able to do secondary to posture-related back pain. Remdesivir was discontinued after 2 days due to acute rise in liver function tests. Over the next few days, the patient began requiring a non-rebreather on 100% in addition to 60L 100% FiO2 HFNC to maintain oxygen saturation. On the morning of 10/22/21, patient began to decompensate with 75% oxygen saturation on 60L 100% HFNC with 100% non rebreather. After reviewing code status with the patient, he requested to be intubated, understanding the risks, benefits, and alternatives. Shortly following successful intubation with 100% FiO2 and PEEP of 14 and arterial line placement, patient continued to decompensate with HR near 130 and hypotension. Despite initiation of vasopressor and optimizing ventilator settings, patient declined and passed away on 10/22/2021 at 10:48am.
Age: 81.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Fatigue, Fibrin D dimer, General physical health deterioration, Hypotension, Intensive care
Clinical narrative: Narrative: Admission date: Oct 10,2021 Discharge Date: Oct 22,2021 Condition of patient at discharge: DECEASED Primary Diagnosis during Admission/Treatment: Acute Hypoxic Respiratory Failure (AHRF) secondary to COVID Pneumonia 80 year old male with a history of CAD s/p PCI to LAD, HFrecEF (51% 12/2020, prev 35% 5/2020) s/p BiV-ICD 9/2020, HTN, and hypothyroidism presented to the Emergency Department (ED) with shortness of breath, cough, and weakness onset 2 weeks prior to the ED visit. Pt stated that he had progressively felt more fatigued and SOB with minimal exertion over the past two weeks and was encouraged to come to the ED by his nephew. He had greenish-yellow sputum production. He also admitted to 2 episodes of non-bloody, nonbilious emesis this morning. He denied any recent CP, lower extremity edema, or subjective fevers at home. In the ED, pt was afebrile, initially satting in the 80's on room air, BP 129/89, tachypneic RR 28. He tested positive for COVID-19 despite 2 doses of Moderna Covid vaccine on 1/11/2021 and 2/8/2021, and had notable labs of Cr 1.45, WBC 18.2, CRP 31.74, ESR 86, procal 1.75, ddimer 2.13. CXR showed mild atelectsis in left lower lobe otherwise clear. CTA PULMONARY ANGIOGRAPHY showed diffuse bilateral peripheral predominant areas of groundglass opacity and crazy paving in the lungs. VBG was 7.44/33.5/13. He was started on CAP coverage rocephin/azithro, given solumedrol 125mg and admitted to the ICU. The patient was started on 10-day course of steroids, remdesivir, and was given antibiotics to cover for possible bacterial co-infection during hospitalization. He started on High Flow Nasal Cannula (HFNC) on maximum settings with oxygen saturations that continued to drop below 88%. Patient was advised to self-prone, but stated that he was not able to do secondary to posture-related back pain. Remdesivir was discontinued after 2 days due to acute rise in liver function tests. Over the next few days, the patient began requiring a non-rebreather on 100% in addition to 60L 100% FiO2 HFNC to maintain oxygen saturation. On the morning of 10/22/21, patient began to decompensate with 75% oxygen saturation on 60L 100% HFNC with 100% non rebreather. After reviewing code status with the patient, he requested to be intubated, understanding the risks, benefits, and alternatives. Shortly following successful intubation with 100% FiO2 and PEEP of 14 and arterial line placement, patient continued to decompensate with HR near 130 and hypotension. Despite initiation of vasopressor and optimizing ventilator settings, patient declined and passed away on 10/22/2021 at 10:48am.
Age: 81.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Liver function test increased, Lung opacity, Mechanical ventilation, Oxygen saturation decreased, Pneumonia
Clinical narrative: Narrative: Admission date: Oct 10,2021 Discharge Date: Oct 22,2021 Condition of patient at discharge: DECEASED Primary Diagnosis during Admission/Treatment: Acute Hypoxic Respiratory Failure (AHRF) secondary to COVID Pneumonia 80 year old male with a history of CAD s/p PCI to LAD, HFrecEF (51% 12/2020, prev 35% 5/2020) s/p BiV-ICD 9/2020, HTN, and hypothyroidism presented to the Emergency Department (ED) with shortness of breath, cough, and weakness onset 2 weeks prior to the ED visit. Pt stated that he had progressively felt more fatigued and SOB with minimal exertion over the past two weeks and was encouraged to come to the ED by his nephew. He had greenish-yellow sputum production. He also admitted to 2 episodes of non-bloody, nonbilious emesis this morning. He denied any recent CP, lower extremity edema, or subjective fevers at home. In the ED, pt was afebrile, initially satting in the 80's on room air, BP 129/89, tachypneic RR 28. He tested positive for COVID-19 despite 2 doses of Moderna Covid vaccine on 1/11/2021 and 2/8/2021, and had notable labs of Cr 1.45, WBC 18.2, CRP 31.74, ESR 86, procal 1.75, ddimer 2.13. CXR showed mild atelectsis in left lower lobe otherwise clear. CTA PULMONARY ANGIOGRAPHY showed diffuse bilateral peripheral predominant areas of groundglass opacity and crazy paving in the lungs. VBG was 7.44/33.5/13. He was started on CAP coverage rocephin/azithro, given solumedrol 125mg and admitted to the ICU. The patient was started on 10-day course of steroids, remdesivir, and was given antibiotics to cover for possible bacterial co-infection during hospitalization. He started on High Flow Nasal Cannula (HFNC) on maximum settings with oxygen saturations that continued to drop below 88%. Patient was advised to self-prone, but stated that he was not able to do secondary to posture-related back pain. Remdesivir was discontinued after 2 days due to acute rise in liver function tests. Over the next few days, the patient began requiring a non-rebreather on 100% in addition to 60L 100% FiO2 HFNC to maintain oxygen saturation. On the morning of 10/22/21, patient began to decompensate with 75% oxygen saturation on 60L 100% HFNC with 100% non rebreather. After reviewing code status with the patient, he requested to be intubated, understanding the risks, benefits, and alternatives. Shortly following successful intubation with 100% FiO2 and PEEP of 14 and arterial line placement, patient continued to decompensate with HR near 130 and hypotension. Despite initiation of vasopressor and optimizing ventilator settings, patient declined and passed away on 10/22/2021 at 10:48am.
Age: 81.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pneumonia viral, Procalcitonin, Red blood cell sedimentation rate increased, SARS-CoV-2 test positive, Sputum discoloured
Clinical narrative: Narrative: Admission date: Oct 10,2021 Discharge Date: Oct 22,2021 Condition of patient at discharge: DECEASED Primary Diagnosis during Admission/Treatment: Acute Hypoxic Respiratory Failure (AHRF) secondary to COVID Pneumonia 80 year old male with a history of CAD s/p PCI to LAD, HFrecEF (51% 12/2020, prev 35% 5/2020) s/p BiV-ICD 9/2020, HTN, and hypothyroidism presented to the Emergency Department (ED) with shortness of breath, cough, and weakness onset 2 weeks prior to the ED visit. Pt stated that he had progressively felt more fatigued and SOB with minimal exertion over the past two weeks and was encouraged to come to the ED by his nephew. He had greenish-yellow sputum production. He also admitted to 2 episodes of non-bloody, nonbilious emesis this morning. He denied any recent CP, lower extremity edema, or subjective fevers at home. In the ED, pt was afebrile, initially satting in the 80's on room air, BP 129/89, tachypneic RR 28. He tested positive for COVID-19 despite 2 doses of Moderna Covid vaccine on 1/11/2021 and 2/8/2021, and had notable labs of Cr 1.45, WBC 18.2, CRP 31.74, ESR 86, procal 1.75, ddimer 2.13. CXR showed mild atelectsis in left lower lobe otherwise clear. CTA PULMONARY ANGIOGRAPHY showed diffuse bilateral peripheral predominant areas of groundglass opacity and crazy paving in the lungs. VBG was 7.44/33.5/13. He was started on CAP coverage rocephin/azithro, given solumedrol 125mg and admitted to the ICU. The patient was started on 10-day course of steroids, remdesivir, and was given antibiotics to cover for possible bacterial co-infection during hospitalization. He started on High Flow Nasal Cannula (HFNC) on maximum settings with oxygen saturations that continued to drop below 88%. Patient was advised to self-prone, but stated that he was not able to do secondary to posture-related back pain. Remdesivir was discontinued after 2 days due to acute rise in liver function tests. Over the next few days, the patient began requiring a non-rebreather on 100% in addition to 60L 100% FiO2 HFNC to maintain oxygen saturation. On the morning of 10/22/21, patient began to decompensate with 75% oxygen saturation on 60L 100% HFNC with 100% non rebreather. After reviewing code status with the patient, he requested to be intubated, understanding the risks, benefits, and alternatives. Shortly following successful intubation with 100% FiO2 and PEEP of 14 and arterial line placement, patient continued to decompensate with HR near 130 and hypotension. Despite initiation of vasopressor and optimizing ventilator settings, patient declined and passed away on 10/22/2021 at 10:48am.
Age: 81.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Tachypnoea, Vomiting, White blood cell count increased
Clinical narrative: Narrative: Admission date: Oct 10,2021 Discharge Date: Oct 22,2021 Condition of patient at discharge: DECEASED Primary Diagnosis during Admission/Treatment: Acute Hypoxic Respiratory Failure (AHRF) secondary to COVID Pneumonia 80 year old male with a history of CAD s/p PCI to LAD, HFrecEF (51% 12/2020, prev 35% 5/2020) s/p BiV-ICD 9/2020, HTN, and hypothyroidism presented to the Emergency Department (ED) with shortness of breath, cough, and weakness onset 2 weeks prior to the ED visit. Pt stated that he had progressively felt more fatigued and SOB with minimal exertion over the past two weeks and was encouraged to come to the ED by his nephew. He had greenish-yellow sputum production. He also admitted to 2 episodes of non-bloody, nonbilious emesis this morning. He denied any recent CP, lower extremity edema, or subjective fevers at home. In the ED, pt was afebrile, initially satting in the 80's on room air, BP 129/89, tachypneic RR 28. He tested positive for COVID-19 despite 2 doses of Moderna Covid vaccine on 1/11/2021 and 2/8/2021, and had notable labs of Cr 1.45, WBC 18.2, CRP 31.74, ESR 86, procal 1.75, ddimer 2.13. CXR showed mild atelectsis in left lower lobe otherwise clear. CTA PULMONARY ANGIOGRAPHY showed diffuse bilateral peripheral predominant areas of groundglass opacity and crazy paving in the lungs. VBG was 7.44/33.5/13. He was started on CAP coverage rocephin/azithro, given solumedrol 125mg and admitted to the ICU. The patient was started on 10-day course of steroids, remdesivir, and was given antibiotics to cover for possible bacterial co-infection during hospitalization. He started on High Flow Nasal Cannula (HFNC) on maximum settings with oxygen saturations that continued to drop below 88%. Patient was advised to self-prone, but stated that he was not able to do secondary to posture-related back pain. Remdesivir was discontinued after 2 days due to acute rise in liver function tests. Over the next few days, the patient began requiring a non-rebreather on 100% in addition to 60L 100% FiO2 HFNC to maintain oxygen saturation. On the morning of 10/22/21, patient began to decompensate with 75% oxygen saturation on 60L 100% HFNC with 100% non rebreather. After reviewing code status with the patient, he requested to be intubated, understanding the risks, benefits, and alternatives. Shortly following successful intubation with 100% FiO2 and PEEP of 14 and arterial line placement, patient continued to decompensate with HR near 130 and hypotension. Despite initiation of vasopressor and optimizing ventilator settings, patient declined and passed away on 10/22/2021 at 10:48am.
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Angiogram pulmonary abnormal, Asthenia, Blood bicarbonate normal, Blood fibrinogen normal, Blood gases normal
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 01/06, Pfizer, dose #1 01/28, Pfizer, dose #2 09/01 pt cc: fatigue exposure: unknown 09/07 ABG: i-pH 7.42, i-PCO2 43.1, i-P02 91, i-HCO3 27.7 09/07 PROCALCITONIN: <0.05 09/07 FERRITIN: 109.2 09/07 FIBRINOGEN: 230 09/07 DDIMER: <0.22 09/07 BNP: 29.3 09/07 TROPONINI: <0.016 09/07 COVID swab, result: detected 09/07 SARS-COV-2 Variant Sequencing result: pending 09/07 CTA PE Impression: No pulmonary embolism. Mild improvement in the chronic bronchiolitis/central airway inflammatory changes in both lungs, mostly notably in the lingula where 7 mm dominant nodule is unchanged. No new alveolar consolidation to favor Covid pneumonia. No pleural effusion. Mild tracheal secretions. 09/07 CXR impression: COPD. No acute pulmonary finding. 09/07 pt admit to ED cc: cough, weakness dx: COVID-19 LOS: 1 DAY
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Blood pH normal, Brain natriuretic peptide normal, Bronchiolitis, COVID-19, Chest X-ray abnormal
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 01/06, Pfizer, dose #1 01/28, Pfizer, dose #2 09/01 pt cc: fatigue exposure: unknown 09/07 ABG: i-pH 7.42, i-PCO2 43.1, i-P02 91, i-HCO3 27.7 09/07 PROCALCITONIN: <0.05 09/07 FERRITIN: 109.2 09/07 FIBRINOGEN: 230 09/07 DDIMER: <0.22 09/07 BNP: 29.3 09/07 TROPONINI: <0.016 09/07 COVID swab, result: detected 09/07 SARS-COV-2 Variant Sequencing result: pending 09/07 CTA PE Impression: No pulmonary embolism. Mild improvement in the chronic bronchiolitis/central airway inflammatory changes in both lungs, mostly notably in the lingula where 7 mm dominant nodule is unchanged. No new alveolar consolidation to favor Covid pneumonia. No pleural effusion. Mild tracheal secretions. 09/07 CXR impression: COPD. No acute pulmonary finding. 09/07 pt admit to ED cc: cough, weakness dx: COVID-19 LOS: 1 DAY
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Chronic obstructive pulmonary disease, Cough, Fatigue, Fibrin D dimer, Increased upper airway secretion
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 01/06, Pfizer, dose #1 01/28, Pfizer, dose #2 09/01 pt cc: fatigue exposure: unknown 09/07 ABG: i-pH 7.42, i-PCO2 43.1, i-P02 91, i-HCO3 27.7 09/07 PROCALCITONIN: <0.05 09/07 FERRITIN: 109.2 09/07 FIBRINOGEN: 230 09/07 DDIMER: <0.22 09/07 BNP: 29.3 09/07 TROPONINI: <0.016 09/07 COVID swab, result: detected 09/07 SARS-COV-2 Variant Sequencing result: pending 09/07 CTA PE Impression: No pulmonary embolism. Mild improvement in the chronic bronchiolitis/central airway inflammatory changes in both lungs, mostly notably in the lingula where 7 mm dominant nodule is unchanged. No new alveolar consolidation to favor Covid pneumonia. No pleural effusion. Mild tracheal secretions. 09/07 CXR impression: COPD. No acute pulmonary finding. 09/07 pt admit to ED cc: cough, weakness dx: COVID-19 LOS: 1 DAY
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Lung opacity, PCO2 normal, PO2 normal, Procalcitonin, Pulmonary mass
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 01/06, Pfizer, dose #1 01/28, Pfizer, dose #2 09/01 pt cc: fatigue exposure: unknown 09/07 ABG: i-pH 7.42, i-PCO2 43.1, i-P02 91, i-HCO3 27.7 09/07 PROCALCITONIN: <0.05 09/07 FERRITIN: 109.2 09/07 FIBRINOGEN: 230 09/07 DDIMER: <0.22 09/07 BNP: 29.3 09/07 TROPONINI: <0.016 09/07 COVID swab, result: detected 09/07 SARS-COV-2 Variant Sequencing result: pending 09/07 CTA PE Impression: No pulmonary embolism. Mild improvement in the chronic bronchiolitis/central airway inflammatory changes in both lungs, mostly notably in the lingula where 7 mm dominant nodule is unchanged. No new alveolar consolidation to favor Covid pneumonia. No pleural effusion. Mild tracheal secretions. 09/07 CXR impression: COPD. No acute pulmonary finding. 09/07 pt admit to ED cc: cough, weakness dx: COVID-19 LOS: 1 DAY
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, SARS-CoV-2 test positive, Serum ferritin normal, Troponin I normal
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 01/06, Pfizer, dose #1 01/28, Pfizer, dose #2 09/01 pt cc: fatigue exposure: unknown 09/07 ABG: i-pH 7.42, i-PCO2 43.1, i-P02 91, i-HCO3 27.7 09/07 PROCALCITONIN: <0.05 09/07 FERRITIN: 109.2 09/07 FIBRINOGEN: 230 09/07 DDIMER: <0.22 09/07 BNP: 29.3 09/07 TROPONINI: <0.016 09/07 COVID swab, result: detected 09/07 SARS-COV-2 Variant Sequencing result: pending 09/07 CTA PE Impression: No pulmonary embolism. Mild improvement in the chronic bronchiolitis/central airway inflammatory changes in both lungs, mostly notably in the lingula where 7 mm dominant nodule is unchanged. No new alveolar consolidation to favor Covid pneumonia. No pleural effusion. Mild tracheal secretions. 09/07 CXR impression: COPD. No acute pulmonary finding. 09/07 pt admit to ED cc: cough, weakness dx: COVID-19 LOS: 1 DAY
Age: 90.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Death, Dyspnoea, Weight increased
Clinical narrative: Narrative:  90y.o. MALE with a h/o HFpEF (EF 56% 1/12/21), COPD on 2L Home o2, paroxysmal a-fib, CKD stage 4-5, DM2, HTN, HLD, Hypothyroidism, who presented to the ED with SOB, weakness and weight gain on 9/21. Pt was transferred to hospice on 10/9/2021. Pt died on 10/10/21. Pt had received covid vaccines on 2/3/21 & 3/4/21. This death is likely not related to the vaccinations due to comorbidities, age, and length of time from vaccine administration.
Age: 86.0
Sex: M
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative:  86yo male patient passed away on October 1 at hospital (non-agency). Pt was in HBPC care with agency. His problem list- PROBLEM LIST: HTN - Hypertension CAD - Coronary Artery Disease Allergic Rhinitis Constipation Hyperlipidemia Incontinence of feces Functional urinary incontinence Glaucoma Vascular dementia without behavioral disturbance Vascular parkinsonism Achalasia of esophagus Atrial fibrillation Congestive heart failure due to left ventricular systolic dysfunction Chronic kidney disease stage 3 Cerebral infarction History of macular degeneration He had received covid vaccines on 3/1/21 & 3/29/21. This death is likely not related to the vaccinations due to comorbidities, age, and length of time from vaccine administration.
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, COVID-19 pneumonia, Death, SARS-CoV-2 test positive, Vaccination failure
Clinical narrative: Narrative:  71yo male patient died of covid positive pneumonia at community hospital (outside agency) on 10/17/2021. Pt had received 3 moderna vaccines on 2/26/21, 3/29/21 & 9/16/21. Patient was a 71 yo male with PMH vtach s/p AICD/pacemaker, NSIP (was on home O2), tongue cancer s/p resection, chemo and radiation. Treatment meds for covid positive infection unknown due to outside agency hospital. Failure of 3 covid vaccines but likely pt was immune compromised given cancer diagnosis.
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Abnormal behaviour, Blood fibrinogen normal, C-reactive protein, COVID-19, Chest X-ray normal
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 01/16, Pfizer, dose #1 02/06, Pfizer, dose #2 09/21, Pfizer, dose #3 09/03 COVID swab, result: detected 09/03 pt cc: exposure: unknown 09/03 FERRITIN: 103.4 09/03 SARS-COV-2 Variant Sequencing result: pending 09/03 ESR: 13 09/03 CXR impression: No acute cardiopulmonary process or significant change since May 23, 2019. Please note chest radiography is not sensitive for detection of findings related to COVID-19 pneumonia. 09/04 pt admit to obs cc: "unable to take care of himself" dx: Covid 19, dementia LOS: 3 days 09/04 FIBRINOGEN: 304 09/04 DDIMER: 13.83 09/04 CRP: 1.688 09/05 FIBRINOGEN: 292 09/05 DDIMER: 1.79 09/05 ESR: 16 09/06 FIBRINOGEN: 281 09/06 DDIMER: 1.31 09/06 ESR: 8 09/07 pt admit to medicine cc: cognitive impairment/ behavioralchanged dx: asymptomatic COVID-19 infection LOS: 21 days 09/07 FIBRINOGEN: 312 09/07 DDIMER: 1.04 09/07 ESR: 37 09/17 clinically resolved
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Cognitive disorder, Dementia, Fibrin D dimer, Loss of personal independence in daily activities, Red blood cell sedimentation rate increased
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 01/16, Pfizer, dose #1 02/06, Pfizer, dose #2 09/21, Pfizer, dose #3 09/03 COVID swab, result: detected 09/03 pt cc: exposure: unknown 09/03 FERRITIN: 103.4 09/03 SARS-COV-2 Variant Sequencing result: pending 09/03 ESR: 13 09/03 CXR impression: No acute cardiopulmonary process or significant change since May 23, 2019. Please note chest radiography is not sensitive for detection of findings related to COVID-19 pneumonia. 09/04 pt admit to obs cc: "unable to take care of himself" dx: Covid 19, dementia LOS: 3 days 09/04 FIBRINOGEN: 304 09/04 DDIMER: 13.83 09/04 CRP: 1.688 09/05 FIBRINOGEN: 292 09/05 DDIMER: 1.79 09/05 ESR: 16 09/06 FIBRINOGEN: 281 09/06 DDIMER: 1.31 09/06 ESR: 8 09/07 pt admit to medicine cc: cognitive impairment/ behavioralchanged dx: asymptomatic COVID-19 infection LOS: 21 days 09/07 FIBRINOGEN: 312 09/07 DDIMER: 1.04 09/07 ESR: 37 09/17 clinically resolved
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, SARS-CoV-2 test positive, Serum ferritin
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 01/16, Pfizer, dose #1 02/06, Pfizer, dose #2 09/21, Pfizer, dose #3 09/03 COVID swab, result: detected 09/03 pt cc: exposure: unknown 09/03 FERRITIN: 103.4 09/03 SARS-COV-2 Variant Sequencing result: pending 09/03 ESR: 13 09/03 CXR impression: No acute cardiopulmonary process or significant change since May 23, 2019. Please note chest radiography is not sensitive for detection of findings related to COVID-19 pneumonia. 09/04 pt admit to obs cc: "unable to take care of himself" dx: Covid 19, dementia LOS: 3 days 09/04 FIBRINOGEN: 304 09/04 DDIMER: 13.83 09/04 CRP: 1.688 09/05 FIBRINOGEN: 292 09/05 DDIMER: 1.79 09/05 ESR: 16 09/06 FIBRINOGEN: 281 09/06 DDIMER: 1.31 09/06 ESR: 8 09/07 pt admit to medicine cc: cognitive impairment/ behavioralchanged dx: asymptomatic COVID-19 infection LOS: 21 days 09/07 FIBRINOGEN: 312 09/07 DDIMER: 1.04 09/07 ESR: 37 09/17 clinically resolved
Age: 91.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Agitation, Angiogram pulmonary abnormal, Blood bicarbonate normal, Blood gases abnormal
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 08/24 pt cc: fatigue exposure: unknown 08/31 Janssen, dose #1 09/05 CTA PE impression: 1. Negative for central PE. 2. Severe multifocal consolidation compatible, greatest at the lower lobes compatible with history of COVID pneumonia. 09/05 CXR impression: 1. Multifocal patchy interstitial and airspace opacities in the mid to lower lung zones, which may represent COVID-19 pneumonia given the history. Superimposed bacterial pneumonia remains a possibility. 2. Possible small bilateral pleural effusions. 09/05 COVID swab, result: detected 09/05 pt admit to medcine cc: confused, agitated, dx: Severe COVID-19 Pneumonia, Acute Hypoxic Respiratory Failure LOS: 2 days 09/05 TROPONIN I: 0.391 09/05 ABG: ABG: i-pH 7.52, i-PCO2 27.9, i-P02 54, i-HCO3 23.0 09/05 DDIMER: 67.14 09/05 LACTIC ACID: 2.18 09/05 PT/INR 14.6/32.3 09/05 BNP: 128.0 09/05 PROCALCITONIN: 0.22 09/05 SARS-COV-2 Variant Sequencing result: pending 09/15 pt deceased
Age: 91.0
Sex: M
Vaccine: COVID19
Symptoms: Blood lactic acid, Blood pH increased, Brain natriuretic peptide increased, COVID-19, COVID-19 pneumonia
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 08/24 pt cc: fatigue exposure: unknown 08/31 Janssen, dose #1 09/05 CTA PE impression: 1. Negative for central PE. 2. Severe multifocal consolidation compatible, greatest at the lower lobes compatible with history of COVID pneumonia. 09/05 CXR impression: 1. Multifocal patchy interstitial and airspace opacities in the mid to lower lung zones, which may represent COVID-19 pneumonia given the history. Superimposed bacterial pneumonia remains a possibility. 2. Possible small bilateral pleural effusions. 09/05 COVID swab, result: detected 09/05 pt admit to medcine cc: confused, agitated, dx: Severe COVID-19 Pneumonia, Acute Hypoxic Respiratory Failure LOS: 2 days 09/05 TROPONIN I: 0.391 09/05 ABG: ABG: i-pH 7.52, i-PCO2 27.9, i-P02 54, i-HCO3 23.0 09/05 DDIMER: 67.14 09/05 LACTIC ACID: 2.18 09/05 PT/INR 14.6/32.3 09/05 BNP: 128.0 09/05 PROCALCITONIN: 0.22 09/05 SARS-COV-2 Variant Sequencing result: pending 09/15 pt deceased
Age: 91.0
Sex: M
Vaccine: COVID19
Symptoms: Chest X-ray abnormal, Confusional state, Death, Fatigue, Fibrin D dimer
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 08/24 pt cc: fatigue exposure: unknown 08/31 Janssen, dose #1 09/05 CTA PE impression: 1. Negative for central PE. 2. Severe multifocal consolidation compatible, greatest at the lower lobes compatible with history of COVID pneumonia. 09/05 CXR impression: 1. Multifocal patchy interstitial and airspace opacities in the mid to lower lung zones, which may represent COVID-19 pneumonia given the history. Superimposed bacterial pneumonia remains a possibility. 2. Possible small bilateral pleural effusions. 09/05 COVID swab, result: detected 09/05 pt admit to medcine cc: confused, agitated, dx: Severe COVID-19 Pneumonia, Acute Hypoxic Respiratory Failure LOS: 2 days 09/05 TROPONIN I: 0.391 09/05 ABG: ABG: i-pH 7.52, i-PCO2 27.9, i-P02 54, i-HCO3 23.0 09/05 DDIMER: 67.14 09/05 LACTIC ACID: 2.18 09/05 PT/INR 14.6/32.3 09/05 BNP: 128.0 09/05 PROCALCITONIN: 0.22 09/05 SARS-COV-2 Variant Sequencing result: pending 09/15 pt deceased
Age: 91.0
Sex: M
Vaccine: COVID19
Symptoms: International normalised ratio increased, Lung consolidation, Lung opacity, PCO2 decreased, PO2 decreased
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 08/24 pt cc: fatigue exposure: unknown 08/31 Janssen, dose #1 09/05 CTA PE impression: 1. Negative for central PE. 2. Severe multifocal consolidation compatible, greatest at the lower lobes compatible with history of COVID pneumonia. 09/05 CXR impression: 1. Multifocal patchy interstitial and airspace opacities in the mid to lower lung zones, which may represent COVID-19 pneumonia given the history. Superimposed bacterial pneumonia remains a possibility. 2. Possible small bilateral pleural effusions. 09/05 COVID swab, result: detected 09/05 pt admit to medcine cc: confused, agitated, dx: Severe COVID-19 Pneumonia, Acute Hypoxic Respiratory Failure LOS: 2 days 09/05 TROPONIN I: 0.391 09/05 ABG: ABG: i-pH 7.52, i-PCO2 27.9, i-P02 54, i-HCO3 23.0 09/05 DDIMER: 67.14 09/05 LACTIC ACID: 2.18 09/05 PT/INR 14.6/32.3 09/05 BNP: 128.0 09/05 PROCALCITONIN: 0.22 09/05 SARS-COV-2 Variant Sequencing result: pending 09/15 pt deceased
Age: 91.0
Sex: M
Vaccine: COVID19
Symptoms: Procalcitonin, Prothrombin time prolonged, SARS-CoV-2 test positive, Troponin I increased
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 08/24 pt cc: fatigue exposure: unknown 08/31 Janssen, dose #1 09/05 CTA PE impression: 1. Negative for central PE. 2. Severe multifocal consolidation compatible, greatest at the lower lobes compatible with history of COVID pneumonia. 09/05 CXR impression: 1. Multifocal patchy interstitial and airspace opacities in the mid to lower lung zones, which may represent COVID-19 pneumonia given the history. Superimposed bacterial pneumonia remains a possibility. 2. Possible small bilateral pleural effusions. 09/05 COVID swab, result: detected 09/05 pt admit to medcine cc: confused, agitated, dx: Severe COVID-19 Pneumonia, Acute Hypoxic Respiratory Failure LOS: 2 days 09/05 TROPONIN I: 0.391 09/05 ABG: ABG: i-pH 7.52, i-PCO2 27.9, i-P02 54, i-HCO3 23.0 09/05 DDIMER: 67.14 09/05 LACTIC ACID: 2.18 09/05 PT/INR 14.6/32.3 09/05 BNP: 128.0 09/05 PROCALCITONIN: 0.22 09/05 SARS-COV-2 Variant Sequencing result: pending 09/15 pt deceased
Age: 26.0
Sex: M
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Asthenia, COVID-19, Cough
Clinical narrative: Narrative: 26yr male was admitted to the agency hospital on 10/12 with COVID sx (fever/weakness/SOB/cough/lost taste and smell) since 10/8 in the setting of recently being diagnosed with COVID(10/10/2021). High risk condition for severe COVID disease: obesity (BMI 43). COVID Therapeutics: Dexamethasone 6mg daily, remdesivir x5 doses, and INV baricitinib 4mg daily. Rapidly increasing oxygen supplementation from 1L NC to requiring high flow O2 within 5 days of hospitalization. Hospitalization stay: 12 days COVID Vaccination Status: Janssen 5/2021
Age: 26.0
Sex: M
Vaccine: COVID19
Symptoms: Disease risk factor, Dyspnoea, Malaise, Pyrexia
Clinical narrative: Narrative: 26yr male was admitted to the agency hospital on 10/12 with COVID sx (fever/weakness/SOB/cough/lost taste and smell) since 10/8 in the setting of recently being diagnosed with COVID(10/10/2021). High risk condition for severe COVID disease: obesity (BMI 43). COVID Therapeutics: Dexamethasone 6mg daily, remdesivir x5 doses, and INV baricitinib 4mg daily. Rapidly increasing oxygen supplementation from 1L NC to requiring high flow O2 within 5 days of hospitalization. Hospitalization stay: 12 days COVID Vaccination Status: Janssen 5/2021
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, COVID-19 pneumonia, Death, SARS-CoV-2 test positive, Vaccination failure
Clinical narrative: Narrative:  62yo pt died of COVID pneumonia on 10/15/2021 at outside hospital Pt self presented to hospital ER on 9/25/2021. No info on treatment meds for covid infection at outside hospital. Patient was a 62 yr old male with history of morbid obesity s/p Gastric Bypass in 2015, hyperlipidemia, hypertension, diabetes on insulin who presented to agency hemetology clinic for evaluation of anemia. Pt had received 2 moderna vaccines on 1/11/21 & 2/8/21. Reporting as death post covid vaccines & as ADE for covid failure as pt covid positive infection & death from this infection after fully vaccinated with 2 moderna covid vaccines.
Age: 80.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Acute respiratory failure, Asthenia, COVID-19, COVID-19 pneumonia, Dyspnoea
Clinical narrative: Narrative:  80 yo male with COPD, history of HTN and BPH, presented to the Emergency Department on 8/27/2021 with worsening dyspnea, fatigue, fever, and weakness. He tested positive for COVID despite being fully vaccinated with Pfizer's Covid vaccine on 2/1/2021 and 2/22/2021. Vital signs were stable and he was given 2-3L O2 via nasal cannula. He was not a remdesivir candidate. He was diagnosed with COVID 19 pneumonia and acute hypoxic respiratory failure and admitted to the hospital. He was treated as above, showed improvement and was discharged on 8/31/2021.
Age: 80.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Fatigue, Pyrexia, SARS-CoV-2 test positive
Clinical narrative: Narrative:  80 yo male with COPD, history of HTN and BPH, presented to the Emergency Department on 8/27/2021 with worsening dyspnea, fatigue, fever, and weakness. He tested positive for COVID despite being fully vaccinated with Pfizer's Covid vaccine on 2/1/2021 and 2/22/2021. Vital signs were stable and he was given 2-3L O2 via nasal cannula. He was not a remdesivir candidate. He was diagnosed with COVID 19 pneumonia and acute hypoxic respiratory failure and admitted to the hospital. He was treated as above, showed improvement and was discharged on 8/31/2021.
Age: 88.0
Sex: M
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative:  87yo male patient died on 9/26/2021. Pt had received covid vaccines from agency on 4/5/21 & 5/5/21. Pt had limited medical care from agency- only opthalmology. No info given regarding pt's death. Also no medical history available in agency records. This death is likely not related to the vaccinations due to advanced age, and length of time from vaccine administration.
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative:  67yo male patient died at HOSPITAL on Oct 11,2021@07:00. Pt with the following comorbidities: Heart Disease Hyperlipidemia Hypothyroidism Diabetes Type II Sleep Apnea Arthritis Lumbar spine DDD dx during specific time Left ankle pain/ ankle fractures during specific time Pt had received covid vaccines on 3/23/21 & 2/23/21. This death is likely not related to the vaccinations due to comorbidities, age, and length of time from vaccine administration.
Age: 70.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Acute respiratory failure, Adenovirus test, Angiogram pulmonary abnormal, Asthenia, Blood lactic acid
Clinical narrative: Narrative:  70-year-old male patient with past medical history most significant for hypertension, hyperlipidemia, diabetes, sleep apnea, anemia, CLL (treated with Ibrutinib), thrombocytopenia, and recent diagnosis of COVID-19 who presented to the Emergency Department complaining of generalized weakness and shortness of breath. Patient was walking from the bathroom back to his chair when he felt so weak that he could not make it all way to his chair. He denied any injuries, head or neck pain, back pain, hip or pelvis pain, extremity pain. EMS was called. He stated he had been short of breath. EMS checked room air saturation several times and stated it was roughly 55%. He was placed on nonrebreather with oxygen saturations in the 70s, then additional 6 L via nasal cannula was added at which point he was satting 88 to 94%. Patient stated that he was feeling well once he was on oxygen. In the ED he was receiving 15 L via nonrebreather satting 89%, placed on HFNC @ 40L & 60% FiO2. He had persistent general malaise/weakness but no focal symptoms. He denied chest pain, palpitations, lightheadedness. He had had no recent fever or chills. He stated he has had recent diffuse mild dull myalgias after his flu shot on 9/23/2021. Otherwise afebrile, BP 144/113, HR 115, RR 20. Labs significant for leukocytosis to 15.5 with left shift, Hgb 9.3, procal 1.57, lactic acid 1.75, d-dimer >20. U/A with 20 ketones. He was admitted on 10/10/2021. On 10/17, the patient had an acute decompensation. He had been weaned to nasal cannula (6L) but had a rapidly increasing oxygen requirement. Subsequent ABG 7.47/34/39, patient in severe respiratory distress. He was intubated and was hypoxic in the 70s despite 100% FIO2. Inhaled NO was started with improvement in hypoxemia. CTPE negative for PE. Source of presume sepsis is due to a superimposed bacterial pneumonia and wide spectrum antibiotics were prescribed. The goal was to wean the patient eventually from the ventilator but on 10/21/2021, the patient had PEA arrest and passed away.